Sector consensus Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 10.50 USD | -6.75% |
|
-10.79% | -33.04% |
| 01/10 | Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102 | CI |
| 01/10 | Monte Rosa Therapeutics, Inc. - Special Call |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 28 | +166.67% | 7 | ||||||
| 187.07 | +11.79% | 18 | ||||||
| 1,172.36 | +27.75% | 15 | ||||||
| 688.17 | +21.67% | 23 | ||||||
| 257.47 | +24.6% | 22 | ||||||
| 288.74 | +11.82% | 19 | ||||||
| 433.52 | +21.07% | 28 | ||||||
| 2,67,741.48 | +46.63% | 22 | ||||||
| 49.73 | +6.77% | 24 | ||||||
| 103.17 | +20.91% | 20 | ||||||
| 197.74 | +77.95% | 23 | ||||||
| 2,453.79 | +8.72% | 15 | ||||||
| 589.92 | -1.59% | 13 | ||||||
| 1,482.61 | +27.26% | 8 | ||||||
| 273.03 | +34.85% | 20 | ||||||
| 72.01 | -3.81% | 14 | ||||||
| 53.93 | -7.63% | 15 | ||||||
| 619.67 | +31.23% | 19 | ||||||
| 305 | +5.1% | 15 | ||||||
| 70.06 | -8.58% | 18 | ||||||
| Average | 13,853.37 | +26.16% | 18 | ||||||
| Weighted average by Cap. | 15,448.41 | +20.68% | 19 |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
